CGEM · Cullinan Therapeutics, Inc.
$17.21
-0.27 (-1.52%)
At close · Jul 29
Market Cap
$1.07B
Shares
61.46M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Nadim Ahmed | CEO | $5,100,006 |
| Jeffrey Jones | Chief Financial Officer | $2,221,578 |
| Mary Kay Fenton | CFO | $2,078,837 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Nadim Ahmed | CEO | $7,684,366 |
| Mary Kay Fenton | CFO | $4,142,413 |
| Jeffrey Trigilio | CFO | $4,002,434 |
| Jeffrey Jones | Chief Financial Officer | $3,388,014 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Nadim Ahmed | CEO | $4,008,206 |
| Jeffrey Jones | Chief Financial Officer | $2,421,669 |
| Jeffrey Trigilio | CFO | $2,204,333 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Nadim Ahmed | CEO | $3,900,527 |
| Patrick Baeuerle | Chief Scientific Officer | $1,959,984 |
| Jeffrey Trigilio | CFO | $1,924,274 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Nadim Ahmed | CEO | $38,547,200 |
| Owen Hughes | CEO | $6,786,187 |
| Patrick Baeuerle | Chief Scientific Officer | $4,675,977 |
| Jeffrey Trigilio | CFO | $2,667,635 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Owen Hughes | CEO | $6,552,058 |
| Patrick Bauerle | Acting Chief Scientific Officer, Biologics | $5,353,497 |
| Patrick Baeuerle | Chief Scientific Officer | $5,353,496 |
| Jon Wigginton | Chief Medical Officer | $4,544,022 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Patrick Bauerle | Acting Chief Scientific Officer, Biologics | $562,797 |
| Owen Hughes | CEO | $560,800 |
Key facts
CIK
1789972
CUSIP
230031106
13F (30d)
25 filings
25 filers
Visit website
Investor relations